查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1954333

疫苗市場分析及預測（至2035年）：類型、產品、技術、應用、最終使用者、流程、給藥方式、材料類型及設備

Vaccines Market Analysis and Forecast to 2035: Type, Product, Technology, Application, End User, Process, Deployment, Material Type, Device
出版日期: | 出版商: Global Insight Services | 英文 349 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

預計疫苗市場規模將從2024年的671億美元成長到2034年的1,380億美元，年複合成長率約為8.1%。疫苗市場涵蓋生物製藥的研發、生產和分銷，這些生物製品能夠提供針對感染疾病的免疫力。這包括針對病毒、細菌和其他病原體的各種疫苗。推動該市場成長的因素包括生物技術的進步、感染疾病率的上升以及政府推廣疫苗接種的措施。疫苗遞送系統的創新，例如mRNA技術和無針注射，對於應對全球健康挑戰和拓展市場機會至關重要。

疫苗市場正經歷強勁成長，這主要得益於生物技術的進步和人們健康意識提升的提高。感染疾病疫苗是推動市場成長的主要動力，其中流感疫苗和肺炎鏈球菌感染疫苗表現特別出色。這些疫苗對於減輕疾病負擔和降低醫療成本至關重要。癌症疫苗緊隨其後，這得歸功於免疫療法和個人化醫療的創新。針對特定癌症類型的治療性疫苗因其改善患者預後的潛力而備受關注。兒童疫苗市場也展現出巨大的潛力，針對麻疹和脊髓灰質炎等疾病的常規免疫接種需求依然強勁。聯合疫苗因其便利性和免疫抗原性，正逐漸成為首選。成人疫苗市場也持續擴張，重點在於增強對帶狀皰疹和肝炎等疾病的免疫力。持續的研發投入和策略合作對於維持市場成長和滿足未被滿足的需求至關重要。

市場區隔
種類 減毒活病毒疫苗、去活化疫苗、次單位疫苗、類毒素疫苗、結合疫苗、DNA疫苗、重組載體疫苗
產品 人用疫苗、獸用疫苗、兒童疫苗、成人疫苗、旅遊疫苗
科技 重組技術、細胞培養技術、基因編輯技術、奈米顆粒技術
適用的 感染疾病、癌症、過敏、神經系統疾病
最終用戶 醫院、診所、研究機構、製藥公司、生技公司、政府機構
過程 研發、製造和分銷
實施表格 本機部署、雲端部署
材料類型 生物來源，合成
裝置 注射器，無針注射器

疫苗市場競爭激烈，各公司透過價格戰和創新產品推出爭奪市場佔有率。這種動態格局受到新疫苗不斷湧現的影響，這些新疫苗旨在應對新出現的健康威脅。各公司會根據市場狀況調整價格，以便在保持盈利的同時提高疫苗的可及性。新配方和給藥系統的持續研發體現了疫苗產業對創新和公共衛生的承諾。疫苗市場競爭異常激烈，主要企業力求透過研發實現差異化。監管具有顯著影響，嚴格的指導方針會影響新產品核可的速度。產業領導者和新興生物技術公司共同塑造了競爭格局，它們利用科學進步來獲得競爭優勢。北美和歐洲等地區的法規結構至關重要，它們塑造著市場動態並影響戰略決策。監管與創新之間的相互作用對決定市場走向至關重要。

主要趨勢和促進因素：

由於全球健康意識的不斷提高和應對疫情的緊迫性，疫苗市場正經歷強勁成長。關鍵趨勢包括快速反應能力強、療效高的mRNA疫苗的加速研發。各國政府正大力投資疫苗研發和生產基礎設施，以確保對新出現的健康威脅做出快速反應。推動因素包括感染疾病的日益普及和全球疫苗接種計劃的擴大。公私合營正在促進創新並支持疫苗分發，尤其是在低收入地區。對個人化醫療的關注也有助於開發針對特定族群的疫苗並提高其療效。此外，生物技術和基因組學的進步正在推動開發具有更高安全性的新一代疫苗。新興市場疫苗接種率的提高帶來了許多機會。專注於創新遞送系統並擴大全球業務的公司將能夠充分利用這些趨勢。隨著世界繼續應對健康挑戰，在科學突破和國際合作的支持下，疫苗市場預計將繼續保持持續成長。

目錄

第1章執行摘要

第2章 市場亮點

第3章 市場動態

  • 宏觀經濟分析
  • 市場趨勢
  • 市場促進因素
  • 市場機遇
  • 市場限制
  • 複合年均成長率：成長分析
  • 影響分析
  • 新興市場
  • 技術藍圖
  • 戰略框架

第4章 細分市場分析

  • 市場規模及預測：依類型
    • 減毒活病毒疫苗
    • 去活化疫苗
    • 次單位疫苗
    • 類毒素疫苗
    • 結合疫苗
    • DNA疫苗
    • 重組載體疫苗
  • 市場規模及預測：依產品分類
    • 人類疫苗
    • 獸用疫苗
    • 兒童疫苗
    • 成人疫苗
    • 旅行疫苗
  • 市場規模及預測：依技術分類
    • 重組技術
    • 細胞培養技術
    • 基因編輯技術
    • 奈米顆粒技術
  • 市場規模及預測：依應用領域分類
    • 感染疾病
    • 癌症
    • 過敏
    • 神經系統疾病
  • 市場規模及預測：依最終用戶分類
    • 醫院
    • 診所
    • 研究所
    • 製藥公司
    • 生技公司
    • 政府機構
  • 市場規模及預測：依製程分類
    • 研究與開發
    • 製造業
    • 分配
  • 市場規模及預測：依發展狀況
    • 本地部署
    • 基於雲端的
  • 市場規模及預測：依材料類型分類
    • 生物製藥
    • 合成
  • 市場規模及預測：依設備分類
    • 注射器
    • 無針注射器

第5章 區域分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地區
  • 亞太地區
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲
    • 台灣
    • 亞太其他地區
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 義大利
    • 其他歐洲地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 撒哈拉以南非洲
    • 其他中東和非洲地區

第6章 市場策略

  • 需求與供給差距分析
  • 貿易和物流限制
  • 價格、成本和利潤率趨勢
  • 市場滲透率
  • 消費者分析
  • 法規概述

第7章 競爭訊息

  • 市場定位
  • 市場占有率
  • 競爭基準
  • 主要企業的策略

第8章 公司簡介

  • Sinovac Biotech
  • Bharat Biotech
  • Cure Vac
  • Novavax
  • Valneva
  • Emergent Bio Solutions
  • VBI Vaccines
  • Dynavax Technologies
  • Inovio Pharmaceuticals
  • Geo Vax Labs
  • Moderna
  • Bio NTech
  • Sanofi Pasteur
  • Glaxo Smith Kline
  • Pfizer
  • Astra Zeneca
  • Johnson & Johnson
  • Merck & Co
  • CSL Limited
  • Seqirus

第9章：關於我們

簡介目錄
Product Code: GIS32548

Vaccines Market is anticipated to expand from $67.1 billion in 2024 to $138.0 billion by 2034, growing at a CAGR of approximately 8.1%. The Vaccines Market encompasses the development, production, and distribution of biological preparations that provide immunity against infectious diseases. It includes a diverse range of vaccines targeting viruses, bacteria, and other pathogens. The market is driven by advancements in biotechnology, rising incidence of infectious diseases, and government initiatives promoting immunization. Innovations in vaccine delivery systems, such as mRNA technology and needle-free administration, are pivotal in addressing global health challenges and expanding market opportunities.

The Vaccines Market is experiencing robust growth, propelled by advancements in biotechnology and increasing awareness of preventive healthcare. The infectious diseases segment leads the market, with vaccines for influenza and pneumococcal infections demonstrating top performance. These vaccines are critical in reducing disease burden and healthcare costs. The cancer vaccines sub-segment follows closely, driven by innovations in immunotherapy and personalized medicine. Therapeutic vaccines targeting specific cancer types are gaining momentum due to their potential to improve patient outcomes. The pediatric vaccines segment also shows significant promise, with routine immunizations for diseases like measles and polio maintaining high demand. Combination vaccines are emerging as a preferred choice, offering convenience and enhanced immunogenicity. The adult vaccines segment is expanding, with a focus on boosting immunity against diseases such as shingles and hepatitis. Continuous research and development, alongside strategic collaborations, are vital in sustaining market growth and addressing unmet medical needs.

Market Segmentation
TypeLive Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Conjugate Vaccines, DNA Vaccines, Recombinant Vector Vaccines
ProductHuman Vaccines, Animal Vaccines, Pediatric Vaccines, Adult Vaccines, Travel Vaccines
TechnologyRecombinant Technology, Cell Culture Technology, Gene Editing Technology, Nanoparticle Technology
ApplicationInfectious Diseases, Cancer, Allergies, Neurological Disorders
End UserHospitals, Clinics, Research Institutes, Pharmaceutical Companies, Biotechnology Companies, Government Organizations
ProcessResearch and Development, Manufacturing, Distribution
DeploymentOn-Premise, Cloud-Based
Material TypeBiological, Synthetic
DeviceSyringes, Needle-Free Injectors

The vaccines market is characterized by a diverse array of players, each vying for market share through competitive pricing strategies and innovative product launches. The dynamic landscape is influenced by the introduction of novel vaccines addressing emerging health threats. Companies are strategically adjusting pricing to enhance accessibility while maintaining profitability. The continuous development of new formulations and delivery systems underscores the industry's commitment to innovation and public health. Competition within the vaccines market is intense, with key players striving for differentiation through research and development. Regulatory influences are significant, with stringent guidelines impacting the pace of new product approvals. The competitive landscape is shaped by industry giants and emerging biotech firms, each leveraging scientific advancements to gain a competitive edge. Regulatory frameworks in regions such as North America and Europe are pivotal, shaping market dynamics and influencing strategic decisions. The interplay between regulation and innovation is crucial in determining market trajectories.

Geographical Overview:

The vaccines market is witnessing robust growth across diverse regions, each presenting unique opportunities. North America remains a dominant player, driven by advanced healthcare infrastructure and substantial public and private investments in vaccine development. The region's focus on innovation and rapid adoption of new technologies bolsters its market position. Europe follows closely, with strong government support for vaccination programs and a well-established pharmaceutical industry. The region's commitment to public health and research excellence further enhances its market dynamics. In Asia Pacific, the market is expanding rapidly, propelled by increasing healthcare expenditure and a growing population. Countries such as China and India emerge as key growth pockets, with significant investments in vaccine research and manufacturing capabilities. Latin America and the Middle East & Africa are emerging markets with considerable potential. In Latin America, rising healthcare awareness and government initiatives drive market growth, while in the Middle East & Africa, improving healthcare infrastructure and increased vaccination efforts present new opportunities.

The global vaccines market is increasingly influenced by tariff impositions and geopolitical tensions, particularly in East Asia. Japan and South Korea are navigating these challenges by enhancing domestic vaccine production capabilities and fostering regional collaborations. China, amid trade tensions, accelerates its vaccine R&D and manufacturing self-sufficiency, while Taiwan focuses on maintaining its strategic position in biotech innovation. The parent market is buoyant, driven by heightened demand for vaccines and technological advancements. By 2035, the market is projected to thrive on diversified supply chains and cross-border partnerships. Meanwhile, Middle East conflicts exacerbate global supply chain vulnerabilities and elevate energy costs, indirectly impacting production and distribution logistics. These dynamics necessitate strategic agility and robust risk management for sustained market growth.

Key Trends and Drivers:

The vaccines market is experiencing robust growth, propelled by heightened global health awareness and the urgent need for pandemic preparedness. Key trends include the accelerated development of mRNA vaccines, which offer rapid response capabilities and strong efficacy. Governments are investing heavily in vaccine research and manufacturing infrastructure, ensuring swift responses to emerging health threats. Drivers include the rising prevalence of infectious diseases and the expanding immunization programs worldwide. Public-private partnerships are fostering innovation and facilitating the distribution of vaccines, particularly in low-income regions. The emphasis on personalized medicine is also encouraging the development of vaccines tailored to specific populations, enhancing their effectiveness. Moreover, technological advancements in biotechnology and genomics are enabling the creation of next-generation vaccines with improved safety profiles. Opportunities abound in emerging markets where vaccination coverage is increasing. Companies focusing on innovative delivery systems and expanding their global footprint are well-positioned to capitalize on these trends. As the world continues to grapple with health challenges, the vaccines market is poised for sustained expansion, driven by scientific breakthroughs and international collaborations.

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Technology
  • 2.4 Key Market Highlights by Application
  • 2.5 Key Market Highlights by End User
  • 2.6 Key Market Highlights by Process
  • 2.7 Key Market Highlights by Deployment
  • 2.8 Key Market Highlights by Material Type
  • 2.9 Key Market Highlights by Device

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Live Attenuated Vaccines
    • 4.1.2 Inactivated Vaccines
    • 4.1.3 Subunit Vaccines
    • 4.1.4 Toxoid Vaccines
    • 4.1.5 Conjugate Vaccines
    • 4.1.6 DNA Vaccines
    • 4.1.7 Recombinant Vector Vaccines
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Human Vaccines
    • 4.2.2 Animal Vaccines
    • 4.2.3 Pediatric Vaccines
    • 4.2.4 Adult Vaccines
    • 4.2.5 Travel Vaccines
  • 4.3 Market Size & Forecast by Technology (2020-2035)
    • 4.3.1 Recombinant Technology
    • 4.3.2 Cell Culture Technology
    • 4.3.3 Gene Editing Technology
    • 4.3.4 Nanoparticle Technology
  • 4.4 Market Size & Forecast by Application (2020-2035)
    • 4.4.1 Infectious Diseases
    • 4.4.2 Cancer
    • 4.4.3 Allergies
    • 4.4.4 Neurological Disorders
  • 4.5 Market Size & Forecast by End User (2020-2035)
    • 4.5.1 Hospitals
    • 4.5.2 Clinics
    • 4.5.3 Research Institutes
    • 4.5.4 Pharmaceutical Companies
    • 4.5.5 Biotechnology Companies
    • 4.5.6 Government Organizations
  • 4.6 Market Size & Forecast by Process (2020-2035)
    • 4.6.1 Research and Development
    • 4.6.2 Manufacturing
    • 4.6.3 Distribution
  • 4.7 Market Size & Forecast by Deployment (2020-2035)
    • 4.7.1 On-Premise
    • 4.7.2 Cloud-Based
  • 4.8 Market Size & Forecast by Material Type (2020-2035)
    • 4.8.1 Biological
    • 4.8.2 Synthetic
  • 4.9 Market Size & Forecast by Device (2020-2035)
    • 4.9.1 Syringes
    • 4.9.2 Needle-Free Injectors

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Technology
      • 5.2.1.4 Application
      • 5.2.1.5 End User
      • 5.2.1.6 Process
      • 5.2.1.7 Deployment
      • 5.2.1.8 Material Type
      • 5.2.1.9 Device
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Technology
      • 5.2.2.4 Application
      • 5.2.2.5 End User
      • 5.2.2.6 Process
      • 5.2.2.7 Deployment
      • 5.2.2.8 Material Type
      • 5.2.2.9 Device
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Technology
      • 5.2.3.4 Application
      • 5.2.3.5 End User
      • 5.2.3.6 Process
      • 5.2.3.7 Deployment
      • 5.2.3.8 Material Type
      • 5.2.3.9 Device
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Technology
      • 5.3.1.4 Application
      • 5.3.1.5 End User
      • 5.3.1.6 Process
      • 5.3.1.7 Deployment
      • 5.3.1.8 Material Type
      • 5.3.1.9 Device
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Technology
      • 5.3.2.4 Application
      • 5.3.2.5 End User
      • 5.3.2.6 Process
      • 5.3.2.7 Deployment
      • 5.3.2.8 Material Type
      • 5.3.2.9 Device
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Technology
      • 5.3.3.4 Application
      • 5.3.3.5 End User
      • 5.3.3.6 Process
      • 5.3.3.7 Deployment
      • 5.3.3.8 Material Type
      • 5.3.3.9 Device
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Technology
      • 5.4.1.4 Application
      • 5.4.1.5 End User
      • 5.4.1.6 Process
      • 5.4.1.7 Deployment
      • 5.4.1.8 Material Type
      • 5.4.1.9 Device
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Technology
      • 5.4.2.4 Application
      • 5.4.2.5 End User
      • 5.4.2.6 Process
      • 5.4.2.7 Deployment
      • 5.4.2.8 Material Type
      • 5.4.2.9 Device
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Technology
      • 5.4.3.4 Application
      • 5.4.3.5 End User
      • 5.4.3.6 Process
      • 5.4.3.7 Deployment
      • 5.4.3.8 Material Type
      • 5.4.3.9 Device
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Technology
      • 5.4.4.4 Application
      • 5.4.4.5 End User
      • 5.4.4.6 Process
      • 5.4.4.7 Deployment
      • 5.4.4.8 Material Type
      • 5.4.4.9 Device
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Technology
      • 5.4.5.4 Application
      • 5.4.5.5 End User
      • 5.4.5.6 Process
      • 5.4.5.7 Deployment
      • 5.4.5.8 Material Type
      • 5.4.5.9 Device
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Technology
      • 5.4.6.4 Application
      • 5.4.6.5 End User
      • 5.4.6.6 Process
      • 5.4.6.7 Deployment
      • 5.4.6.8 Material Type
      • 5.4.6.9 Device
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Technology
      • 5.4.7.4 Application
      • 5.4.7.5 End User
      • 5.4.7.6 Process
      • 5.4.7.7 Deployment
      • 5.4.7.8 Material Type
      • 5.4.7.9 Device
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Technology
      • 5.5.1.4 Application
      • 5.5.1.5 End User
      • 5.5.1.6 Process
      • 5.5.1.7 Deployment
      • 5.5.1.8 Material Type
      • 5.5.1.9 Device
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Technology
      • 5.5.2.4 Application
      • 5.5.2.5 End User
      • 5.5.2.6 Process
      • 5.5.2.7 Deployment
      • 5.5.2.8 Material Type
      • 5.5.2.9 Device
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Technology
      • 5.5.3.4 Application
      • 5.5.3.5 End User
      • 5.5.3.6 Process
      • 5.5.3.7 Deployment
      • 5.5.3.8 Material Type
      • 5.5.3.9 Device
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Technology
      • 5.5.4.4 Application
      • 5.5.4.5 End User
      • 5.5.4.6 Process
      • 5.5.4.7 Deployment
      • 5.5.4.8 Material Type
      • 5.5.4.9 Device
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Technology
      • 5.5.5.4 Application
      • 5.5.5.5 End User
      • 5.5.5.6 Process
      • 5.5.5.7 Deployment
      • 5.5.5.8 Material Type
      • 5.5.5.9 Device
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Technology
      • 5.5.6.4 Application
      • 5.5.6.5 End User
      • 5.5.6.6 Process
      • 5.5.6.7 Deployment
      • 5.5.6.8 Material Type
      • 5.5.6.9 Device
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Technology
      • 5.6.1.4 Application
      • 5.6.1.5 End User
      • 5.6.1.6 Process
      • 5.6.1.7 Deployment
      • 5.6.1.8 Material Type
      • 5.6.1.9 Device
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Technology
      • 5.6.2.4 Application
      • 5.6.2.5 End User
      • 5.6.2.6 Process
      • 5.6.2.7 Deployment
      • 5.6.2.8 Material Type
      • 5.6.2.9 Device
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Technology
      • 5.6.3.4 Application
      • 5.6.3.5 End User
      • 5.6.3.6 Process
      • 5.6.3.7 Deployment
      • 5.6.3.8 Material Type
      • 5.6.3.9 Device
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Technology
      • 5.6.4.4 Application
      • 5.6.4.5 End User
      • 5.6.4.6 Process
      • 5.6.4.7 Deployment
      • 5.6.4.8 Material Type
      • 5.6.4.9 Device
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Technology
      • 5.6.5.4 Application
      • 5.6.5.5 End User
      • 5.6.5.6 Process
      • 5.6.5.7 Deployment
      • 5.6.5.8 Material Type
      • 5.6.5.9 Device

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Sinovac Biotech
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Bharat Biotech
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Cure Vac
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Novavax
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Valneva
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Emergent Bio Solutions
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 VBI Vaccines
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Dynavax Technologies
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Inovio Pharmaceuticals
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Geo Vax Labs
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Moderna
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Bio NTech
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Sanofi Pasteur
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Glaxo Smith Kline
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Pfizer
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 Astra Zeneca
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Johnson & Johnson
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 Merck & Co
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 CSL Limited
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 Seqirus
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us